Annis Gardner Whiting Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Annis Gardner Whiting Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$860K	Sell	1,925 -39	-2%	-$18.2K	0.14%	130
2025 Q4	$890K	Sell	1,964 -3	-0.2%	-$1.29K	0.17%	110
2025 Q3	$770K	Buy	1,967 +6	+0.3%	+$2.51K	0.16%	111
2025 Q2	$873K	Buy	1,961 +22	+1%	+$10.1K	0.3%	73
2025 Q1	$940K	Sell	1,939 -5	-0.3%	-$2.33K	0.4%	56
2024 Q4	$783K	Hold	1,944	–	–	0.22%	84
2024 Q3	$904K	Sell	1,944 -61	-3%	-$29.3K	0.25%	75
2024 Q2	$940K	Buy	2,005 +1,809	+923%	+$785K	0.27%	70
2024 Q1	$81.9K	Buy	196 +40	+26%	+$16.9K	0.03%	311
2023 Q4	$63.5K	Hold	156	–	–	0.03%	273
2023 Q3	$54.2K	Buy	+156	New	+$54.6K	0.03%	275

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Annis Gardner Whiting Capital Advisors's VRTX Position: Q1 2026 in Review

Annis Gardner Whiting Capital Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 2% in Q1 2026, selling an estimated $18.2K and leaving 1,925 shares worth $860K. The position accounts for 0.14% of the portfolio, ranked #130.

Annis Gardner Whiting Capital Advisors first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $940K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Annis Gardner Whiting Capital Advisors held 1,925 shares of Vertex Pharmaceuticals worth $860K as of Q1 2026.
Annis Gardner Whiting Capital Advisors sold 39 Vertex Pharmaceuticals shares in Q1 2026, an estimated $18.2K.
Vertex Pharmaceuticals made up 0.14% of Annis Gardner Whiting Capital Advisors's portfolio in Q1 2026, its #130 holding.
Annis Gardner Whiting Capital Advisors first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Annis Gardner Whiting Capital Advisors's Vertex Pharmaceuticals position peaked at $940K in Q1 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Annis Gardner Whiting Capital Advisors's 13F filing for Q1 2026, filed 6 May 2026.